Association of Clara cell 10-kDa protein, spontaneous regression and sarcoidosis


ABSTRACT: Sarcoidosis is a systemic granulomatous disorder with a high rate of spontaneous regression. Clara cell 10-kDa protein (CC10), the predominant product of nonciliated bronchiolar epithelial cells, is a potent immunoregulatory and anti-inflammatory agent.

CC10 levels were measured in sera and bronchoalveolar lavage (BAL) fluids from 31 sarcoidosis patients (nine progressive disease and 22 regressive disease) and their correlation with outcome of disease in sarcoidosis investigated. The inhibitory effects of recombinant CC10 on interferon gamma (IFN-γ) production were also tested.

Serum and BAL fluid CC10 levels in the regressive disease group were significantly higher than those in the progressive disease group (serum, p<0.05; BAL fluid, p<0.005) and healthy subjects (serum, p<0.0001; BAL fluid, p<0.005). CC10 inhibited, in part, IFN-γ production from LPS-stimulated sarcoid BAL fluid cells (CC10 inhibition: 1,000 ng mL⁻¹, 30%; 100 ng mL⁻¹, 14%). TY-5 restored IFN-γ production by blocking CC10 function.

Sarcoidosis patients with regressive disease showed increased Clara cell 10-kDa protein levels in their sera and bronchoalveolar lavage fluids. Clara cell 10-kDa protein may be a regulator of the inflammatory process in sarcoidosis.


In sarcoidosis, the unknown causative agent leads to the accumulation of activated CD4+ lymphocytes releasing the T-helper cell 1 cytokines interleukin (IL)-2 and interferon gamma (IFN-γ) at sites of inflammation and granuloma formation [1]. Despite the systemic nature of the disease, T-cell and macrophage/monocyte activation are restricted to the involved organs. In ~60% of patients with sarcoidosis, spontaneous regression is observed [2, 3]. Mechanisms downregulating inflammation are present in sarcoidosis, however, the prerequisites or mechanisms for induction of spontaneous regression are unknown.

Clara cell 10-kDa protein (CC10) is the predominant product of nonciliated bronchiolar epithelial cells (Clara cells) in respiratory and terminal bronchioles in the lung [4]. Human CC10 has been proven identical to human protein 1 (Pt1) [5] and uteroglobin (UG) [6]. CC10/UG possesses various biochemical and biological properties, including phospholipase A2 (PLA2)- [7] and phospholipase C (PLC)-inhibitory activity [8]. CC10 shows potent inhibition of IFN-γ, tumour necrosis factor-α (TNF-α) and IL-1β [9, 10]. In addition, CC10 deficiency results in increased sensitivity to hypoxia-induced lung injury by increasing pro-inflammatory cytokine expression [11]. The evidence has led to speculation that CC10 may function as a downregulator of airway inflammation.

The aims of the present study were to investigate CC10 levels in sera and bronchoalveolar lavage (BAL) fluids and their correlation with outcome of disease in sarcoidosis patients, and to test the inhibitory effects of CC10 on IFN-γ production from sarcoid BAL fluid cells.

Materials and methods

Subjects

Only lifelong nonsmokers were selected for this study, because tobacco smoking has been associated with an ~30% decrease in serum CC10 levels and an ~50% decrease in BAL fluid CC10 levels [12, 13].

Patients

Thirty-one lifelong nonsmokers (mean age 47±20 yrs; four male and 27 female) were selected from among 148 patients with sarcoidosis who visited our hospitals (Sapporo Medical University School of Medicine and Sapporo Hospital of Hokkaido Railways Company) between 1992 and 1996 (first series). They exhibited histological findings consistent with sarcoidosis (noncaseating epithelioid cell...
granulomas) in the lung, without evidence of mycobacterial, fungal or parasitic infection. None had a history of exposure to organic or inorganic materials known to cause granulomatous lung diseases. They had not received corticosteroid therapy.

Nine patients had stage 0 sarcoidosis (clear chest radiograph); 12 had stage 1 (hilar lymphadenopathy); seven had stage 2 (hilar lymphadenopathy and pulmonary infiltrates); and three had stage 3 (pulmonary infiltrates without hilar lymphadenopathy). They were followed-up for $\geq 3$ yrs.

In all stages, the extrapulmonary lesions progressed on chest radiography and/or chest computed tomography (CT) for $\geq 3$ yrs (progressive disease group), and, in 20, the intrathoracic lesions disappeared spontaneously or regressed within 3 yrs without any therapy (regressive disease group). Two patients were treated with corticosteroids for long periods due to progression of pulmonary or bone sarcoidosis (progressive disease group). In two patients (stage 1 and stage 2), the ocular lesions greatly improved with short-term (4–8 week) corticosteroid therapy; within 3 yrs after therapy, intrathoracic lesions relapsed in one patient (progressive disease group), and the remaining patient did not have any recurrence (regressive disease group).

Expression and purification of recombinant human Clara cell 10-kDa protein

Using a pET expression system, recombinant human CC10 was obtained from Escherichia coli culture as described previously [8, 14]. Recombinant human CC10 was purified using anti-CC10/P1 monoclonal antibody (MoAb) 6D4-conjugated Sepharose 4B (Pharmacia, Uppsala, Sweden) and reverse-phase high-performance liquid chromatography (Bondasphere mm C4-300A; Waters, Milford, MA, USA), as described previously [8, 14]. The 20 amino-terminal amino acid residues of purified recombinant CC10 were identical to those of native protein except for an additional methionine at the amino-terminus of recombinant human CC10, when determined with gas-phase amino acid sequencer model PPSQ-10 (Shimazu, Kyoto, Japan) according to the manufacturer’s instructions.

Monoclonal antibodies to human Clara cell 10-kDa protein

Nine MoAbs (6D4, TY-1, TY-2, TY-3, TY-4, TY-5, TY-6, TY-7 and TY-8) to human CC10/P1 were produced [14]. CC10 is a homodimer consisting of 70-amino acid subunits arranged in an antiparallel fashion and connected by two disulphide bonds. Epitopes recognized by these clones were analysed as described previously [14]. The clones TY-1 and TY-2 recognized residues 61–68, which are exposed to solvent. A sensitive sandwich enzyme-linked immunosorbent assay (ELISA) was developed using TY-1 and TY-2, selected from among the MoAbs [14, 15]. The clone TY-5 recognized residues 7–16 of CC10, which make up the hydrophobic cavity of CC10, possibly associated with chemical-binding function. The binding of TY-5 to CC10 prevents the other clones from binding to CC10. Only the clone TY-5 showed significant binding to CC10. The results of BAL fluid analysis of healthy subjects and sarcoidosis patients (first and second series) are shown in table 1.

Table 1. – Characteristics of bronchoalveolar lavage fluid analysis

<table>
<thead>
<tr>
<th></th>
<th>Healthy subjects</th>
<th>Sarcoidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First series</td>
<td>Second series</td>
</tr>
<tr>
<td>Subjects n</td>
<td>15</td>
<td>31</td>
</tr>
<tr>
<td>Recovery rate %</td>
<td>66.3±10.8</td>
<td>63.5±13.5</td>
</tr>
<tr>
<td>Total cell counts 10⁴ cells·mL⁻¹</td>
<td>12.8±7.1</td>
<td>15.8±12.4</td>
</tr>
<tr>
<td>Alveolar macrophages 10⁴ cells·mL⁻¹</td>
<td>10.6±5.8</td>
<td>10.3±7.7</td>
</tr>
<tr>
<td>Lymphocytes 10⁴ μg·mL⁻¹</td>
<td>2.1±0.5</td>
<td>5.5±2.6*</td>
</tr>
<tr>
<td>Neutrophils 10⁴ μg·mL⁻¹</td>
<td>0.04±0.02</td>
<td>0.09±0.05</td>
</tr>
<tr>
<td>Albumin 10⁶ cells·mL⁻¹</td>
<td>39.1±12.1</td>
<td>47.4±18.7</td>
</tr>
<tr>
<td>CC10 10⁴ cells·mL⁻¹</td>
<td>757±418</td>
<td>1100±772</td>
</tr>
</tbody>
</table>

Data are presented as mean±sd. *: p<0.005; **: p<0.01 versus healthy subjects.
binding, suggesting that TY-5 induces strong conformational changes in CC10 [14].

Quantitation of Clara cell 10-kDa protein

CC10 concentrations were measured via an ELISA employing MoAbs TY-1 and TY-2 to human CC10/Pi, as described previously [15]. Briefly, plastic immunoplates (Nunc, Copenhagen, Denmark) were coated with MoAb TY-2 (1 mg·L⁻¹) in 50 μL carbonate buffer (pH 9.6) overnight at 4°C. Unbound MoAb was removed by washing with 0.05% Tween 20 in 0.05 M phosphate-buffered saline (PBS-T) (pH 7.0) and then coated with 100 μL 1% bovine serum albumin in PBS-T (BSA-PBS-T). To this, 100 μL of standard or diluted samples were added and allowed to react with the coated antibody for 60 min at 37°C. Unbound antigen was removed by washing with PBS-T. Biotinylated MoAb TY-1 (100 μL, 1 mg·L⁻¹) in BSA-PBS-T was added, and the mixture incubated for 60 min at 37°C. The material was then washed with the same buffer, 100 μL of streptavidin/ peroxidase-conjugated goat antimouse immunoglobulin (diluted 1:1,000 in BSA-PBS-T) added and the mixture again incubated for another 30 min at 37°C. After repeated washing with the same buffer, the unbound enzyme conjugate was removed. At this point, 100 μL enzyme substrate containing 1 mg·mL⁻¹ o-phenylenediamine in citrate buffer (pH 5.0) and 0.03% (volume/volume) hydrogen peroxide was added. Enzyme activity was measured by determining absorbance at 490 nm after terminating the reaction with 150 μL 1.0 M sulphuric acid. Purification of standard antigen was performed as previously described [13, 16]. Mean coefficients of variation of intra-assay and interassay accuracy were 5.2% (range 4.7–5.9%) and 7.2% (range 6.2–8.6%), respectively [15]. CC10 concentrations can be determined in the range 4–1,000 pg·mL⁻¹. Mean coefficients of variation of intra-assay and interassay precision were 5.5 and 6.0%, respectively. The assay system showed no cross-reactivity with other human cytokines.

Statistical analysis

Data are expressed as means±SD. The Mann-Whitney U-test or paired t-test was used to compare paired sets of data. Pearson least squares linear regression analysis was used to determine correlation. A p-value of <0.05 was considered significant.

Results

Serum and bronchoalveolar lavage fluid Clara cell 10-kDa protein levels and their correlation

The serum CC10 levels of patients with sarcoidosis (19.5±8.60 ng·mL⁻¹, range 6.92–42.3 ng·mL⁻¹) were significantly increased as compared with healthy subjects (11.6±3.85 ng·mL⁻¹, range 5.16–22.4 ng·mL⁻¹; p<0.0001) (fig. 1). There were no significant differences in serum CC10 levels according to radiological stage (stage 0, 19.2±11.0 ng·mL⁻¹; stage 1, 18.7±6.2 ng·mL⁻¹; stage 2, 21.4±11.0 ng·mL⁻¹; and stage 3, 18.8±5.0 ng·mL⁻¹).

There was no significant difference in CC10 levels in BAL fluids from healthy subjects (757±418 ng·mL⁻¹) and sarcoidosis patients (1,100±772 ng·mL⁻¹) (table 1 and fig. 2). No significant difference in BAL fluid CC10/albumin ratios was found between healthy subjects (18.7±9.1 ng·μg⁻¹) and sarcoidosis patients (25.8±16.6 ng·μg⁻¹). There were no significant differences in BAL fluid CC10 levels according to radiological stage (stage 0, 1,110±671 ng·mL⁻¹; stage 1, 1,050±780 ng·mL⁻¹; stage 2, 1,330±1,040 ng·mL⁻¹; and stage 3, 676±311 ng·mL⁻¹). No significant differences in BAL fluid CC10/albumin ratios were found according to radiological stage (stage 0, 26.5±13.1 ng·μg⁻¹; stage 1, 24.2±18.7 ng·μg⁻¹; stage 2, 29.6±20.0 ng·μg⁻¹; and stage 3, 20.6±14.0 ng·μg⁻¹).

There was a significant positive correlation in CC10 levels between sera and BAL fluids from sarcoidosis patients (r=0.759, p<0.0001) (fig. 3).

Relationship of Clara cell 10-kDa protein levels to clinical outcome

Relationships of serum and BAL fluid CC10 levels to clinical outcome were analysed in the 31 patients with sarcoidosis. The mean CC10 levels in serum (21.7±9.13 ng·mL⁻¹) and BAL fluid (1,560±751 ng·mL⁻¹) in the regressive disease group were significantly higher than those
in the progressive disease group (serum, 14.2±3.70 ng·mL⁻¹, p<0.05; BAL fluid, 458±328 ng·mL⁻¹, p<0.005) and those in the healthy subjects (p<0.0001 and p<0.005, respectively).

In contrast, there were no significant differences in serum or BAL fluid CC10 levels between the progressive disease group and healthy subjects. In addition, the mean BAL fluid CC10/albumin ratio (31.7±15.0 ng·µg⁻¹) was significantly higher in the regressive disease group than in the progressive group (11.3±10.3 ng·µg⁻¹, p<0.005) and healthy controls (p<0.005). There was no significant difference in BAL fluid CC10/albumin ratios between the progressive disease group and healthy controls.

Effects of recombinant Clara cell 10-kDa protein on interferon gamma production in bronchoalveolar lavage fluid cells

LPS-stimulated sarcoid BAL fluid cells produced IFN-γ (871±382 ng·mL⁻¹). CC10 reduced IFN-γ production by LPS-stimulated sarcoid BAL fluid cells (CC10 1,000 ng·mL⁻¹: 30.3±17.6% inhibition, range 11.7–54.9%; CC10 100 ng·mL⁻¹: 14.0±14.8% inhibition, range 1.2–46.5%) (fig. 4). However, there was no significant difference in the percentage of inhibition of IFN-γ production by CC10 in LPS-stimulated sarcoid BAL fluid cells between the stage 1 and stage 2 disease groups. When correlation of the percentage of inhibition of IFN-γ production by CC10 (100 and 1,000 ng·mL⁻¹) was analysed with numbers of alveolar macrophages and lymphocytes, there was no significant correlation of the percentage of inhibition with cell subsets. The MoAb TY-5 restored IFN-γ production by blocking CC10 function (fig. 5).

Discussion

Significantly increased levels of serum and BAL fluid CC10 in sarcoidosis patients with regressive disease compared with those with progressive disease and with healthy subjects were found in the present study. Recombinant CC10 inhibited IFN-γ production by LPS-stimulated sarcoid BAL fluid cells and MoAb TY-5 to CC10 restored IFN-γ production by blocking CC10 function.

CC10 plays an important immunoregulatory and anti-inflammatory role in the lung. It has been shown to inhibit the activity of PLA₂, a key enzyme in inflammatory phenomena [6]. Johnston et al. [11] reported increased sensitivity to hyperoxia-induced lung injury and an exaggerated inflammatory response in CC10-deficient mice. In an animal model, CC10 messenger ribonucleic acid was upregulated by IFN-γ [16]. CC10 production by human airway epithelial cells was stimulated by TNF-α [18]. Several lines of evidence support the hypothesis that CC10 functions as a downregulator and a counterregulator of inflammation.

CC10 levels in sera and BAL fluids have been reported in various lung diseases [13, 19–24]. Decreases in CC10 levels have been found in the BAL fluids of patients with asthma [19], idiopathic pulmonary fibrosis [20], and chronic obstructive pulmonary disease [21] and in the
sera of patients with asthma [22], chronic obstructive pulmonary disease [21] and bacterial pneumonia [23]. Increases in CC10 level have been found in the BAL fluids of patients with asbestosis [24]. A recent observation showed reduced numbers of CC10-positive epithelial cells in the small airways of patients with asthma [25]. The present study documented increased CC10 levels in the sera of patients with sarcoidosis, but not in BAL fluids, consistent with a prior report [21]. Increased CC10 levels in sera and BAL fluids from sarcoidosis patients with regressive disease were documented in the present study. In this study, control BAL fluid samples were obtained from considerably younger healthy subjects. It is difficult to obtain BAL fluid samples for healthy subjects from age- and sex-matched sarcoidosis patients, because all life-long nonsmoker sarcoidosis patients were considerably old and many of the patients were female with very few male patients. This study also demonstrated a positive correlation between serum and BAL fluid CC10 levels in sarcoidosis patients, suggesting that serum CC10 levels reflect CC10 production in lung cells under disease condition as well as in healthy subjects [12, 21]. In the present study, recombinant CC10 reduced, in part, IFN-γ production by LPS-stimulated sarcoid BAL fluid cells. Native CC10/P1 inhibited IFN-γ production by phytohaemagglutinin-stimulated peripheral blood mononuclear cells from a healthy donor [9]. CC10 reduced the biological action of IFN-γ such as antiviral activity and phagocytosis-stimulating activity [9]. Native CC10/P1 induced PLA2-mediated inhibition of fibroblast migration [20]. Recombinant CC10 inhibited PLA2 and PLC activities in a dose-dependent manner [8, 26]. Recombinant CC10/UG blocked fibroblast-conditioned medium-stimulated cancer cell migration in a dose-dependent manner [27]. Recombinant CC10/UG suppressed extracellular matrix invasion by normal and cancer cells that expressed high-affinity receptors for CC10/UG [28, 29]. Several lines of evidence indicate that there are no significant functional differences between native and recombinant CC10. In addition, although speculative, the inhibitory effects of CC10 on IFN-γ production from sarcoid BAL fluid cells may depend on the expression of high-affinity CC10-binding receptors of BAL fluid cells.

The present study demonstrated that MoAb TY-5, specific to human CC10, restored IFN-γ production by blocking CC10 function. TY-5 recognized residues 7–16 of CC10, which make up the hydrophobic cavity [14]. The binding of TY-5 to CC10 prevented the other MoAbs from binding to CC10, suggesting that TY-5 induced strong conformational change in CC10 [14]. To the authors’ knowledge, this is the first report demonstrating that MoAb specific to human CC10 restores the inhibitory function of CC10 by neutralizing CC10. The evidence suggests that CC10 is a downregulator in sarcoidosis patients and that high levels of CC10 in inflamed lesions could reduce inflammation and cytokine production from sarcoid lesions, resulting in disease regression in sarcoidosis. The lungs and eyes are the organs most commonly affected in sarcoidosis; interestingly, CC10 immunoreactivity has been found in the eyes [30] as well as in Clara cells in the lung. The A38G polymorphism of human CC10 has been found in asthmatic children [31]. This polymorphism has been associated with reduced levels of serum CC10 and an increased risk of developing asthma [31]. In addition, homozygous 38A subjects demonstrated reduced plasma CC10 levels as compared to heterozygotes and homozygous 38G subjects within the nonasthmatic group [31]. Although speculative, the A38G polymorphism in the untranslated region of the CC10 gene may be related to CC10 production in response to IFN-γ and TNF-α, reflected in the clinical outcome of sarcoidosis. Additional studies are needed to evaluate the association of CC10 levels with the A38G polymorphism of patients with sarcoidosis.

In conclusion, serum and bronchoalveolar lavage fluid samples from sarcoidosis patients with regressive disease
contain significantly higher levels of Clara cell 10-kDa protein, and human Clara cell 10-kDa protein inhibits interferon gamma production by lipopolysaccharide-stimulated sarcoid bronchoalveolar lavage fluid cells. The evidence indicates the importance of Clara cell 10-kDa protein as a regulator of airway inflammation in sarcoidosis patients.

References